Product Description
Mechanisms of Action: RPE65 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Stargardt Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kubota Vision
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Macular Degeneration|Geographic Atrophy|Stargardt Disease
Phase 2: Macular Degeneration|Anetoderma|Stargardt Disease|Geographic Atrophy|Diabetic Retinopathy
Phase 1: Geographic Atrophy|Macular Degeneration|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02130531 |
NCT02130531 | P1 |
Completed |
Geographic Atrophy|Macular Degeneration |
2015-09-01 |
2020-07-05 |
Primary Endpoints|Treatments |
|
NCT00942240 |
NCT00942240 | P1 |
Completed |
Healthy Volunteers |
2010-04-01 |
2020-07-05 |
Primary Endpoints|Treatments |
|
NCT00703183 |
NCT00703183 | P1 |
Completed |
Healthy Volunteers |
2009-06-01 |
2020-07-05 |
Primary Endpoints|Treatments |
|
NCT03033108 |
NCT03033108 | P2 |
Completed |
Macular Degeneration|Stargardt Disease|Anetoderma |
2017-11-01 |
2021-04-28 |
||
NCT02753400 |
NCT02753400 | P2 |
Completed |
Diabetic Retinopathy |
2017-11-01 |
2021-05-20 |
Primary Endpoints|Start Date|Treatments |
|
NCT01002950 |
Geographic Atrophy | P2 |
Completed |
Macular Degeneration|Geographic Atrophy |
2012-06-01 |
2020-07-05 |
Primary Endpoints|Treatments |
|
2018-003498-82 |
The SeaSTAR Study (Safety and efficacy of EmixustAt in STARgardt disease) | P3 |
Unknown status |
Stargardt Disease |
2022-11-18 |
2025-05-06 |
Treatments |
|
NCT03772665 |
SeaSTAR | P3 |
Completed |
Macular Degeneration|Stargardt Disease |
2022-06-13 |
16% |
2024-05-31 |
|
2012-004952-12 |
2012-004952-12 | P3 |
Completed |
Macular Degeneration|Geographic Atrophy |
2016-04-15 |
2025-07-04 |
Treatments |
|
NCT01802866 |
SEATTLE | P3 |
Completed |
Geographic Atrophy |
2016-04-01 |
2020-07-05 |
Primary Endpoints|Treatments |